VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

RCN-rabies-G
Vaccine Information
  • Vaccine Name: RCN-rabies-G
  • Target Pathogen: Rabies virus
  • Target Disease: Rabies
  • Vaccine Ontology ID: VO_0004693
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Glycoprotein G gene engineering:
    • Type: Recombinant vector construction
    • Description: A recombinant RCN vaccine expressing the rabies-G glycoprotein (RCN/rabies-G) (Osorio et al., 1999).
    • Detailed Gene Information: Click Here.
  • Vector: raccoon poxvirus vaccine vector
  • Preparation: Recombinant RCN vaccine expressing the rabies-G glycoprotein (RCN/rabies-G) (Osorio et al., 2003).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Cat Response

  • Vaccination Protocol: The cats were vaccinated by the oral (PO), intranasal (IN), conjunctival (CO) or intranasal/conjunctival (IN/CO) route (dose: 10 plaque forming units or PFU) (Osorio et al., 2003).
  • Vaccine Immune Response Type: VO_0000287
  • Challenge Protocol: Because of humanitarian concerns, we did not perform rabies virus challenge on these cats. However, RVNA titers of 1:5 (0.69 log10) or greater in humans have been correlated with vaccine protection (Smith et al., 1996). Thus, it is reasonable to surmise that the high RVNA titers observed in the immunized cats could provide protection against challenge (Osorio et al., 2003).
  • Efficacy: The RVNA titers remained high when measured at six months post-vaccination, demonstrating that the recombinant vaccine administered via these routes is very efficient at inducing long-lasting immunity (Osorio et al., 2003).
References
Osorio et al., 1999: Osorio JE, Tomlinson CC, Frank RS, Haanes EJ, Rushlow K, Haynes JR, Stinchcomb DT. Immunization of dogs and cats with a DNA vaccine against rabies virus. Vaccine. 1999; 17(9-10); 1109-1116. [PubMed: 10195621].
Osorio et al., 2003: Osorio JE, Frank RS, Moss K, Taraska T, Powell T, Stinchcomb DT. Raccoon poxvirus as a mucosal vaccine vector for domestic cats. Journal of drug targeting. 2003; 11(8-10); 463-470. [PubMed: 15203914].